508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
68 citations
,
September 2003 in “British Journal of Dermatology” This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
2 citations
,
February 2021 in “Indian Dermatology Online Journal” This case report describes the first instance of classical lichen planopilaris with atrophic lichenoid plaques developing in a Blaschko-linear pattern due to imatinib treatment in a patient with chronic myeloid leukemia.
1 citations
,
April 2004 in “Cancer” This study describes that 65% of patients receiving imatinib mesylate in a patient assistance program experienced skin hypopigmentation, primarily in ethnically Chinese individuals, suggesting variability across populations.